Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 11/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647462 | 0.78 | ERN1 (0.50) | PIM1ERN1 | |
| SCHEMBL704959 | 0.73 | BCL2L1 (0.41) | ERN1TRIM24TRIM33 | |
| SCHEMBL19249611 | 0.72 | BCL2L1 (0.39) | ERN1TRIM24TRIM33 | |
| SCHEMBL24133365 | 0.71 | ERN1 (0.50) | ERN1 | |
| SCHEMBL6682317 | 0.71 | CTRC (0.50) | ERN1TRIM24TRIM33 | |
| SCHEMBL835332 | 0.71 | ERN1 (0.45) | ERN1 | |
| SCHEMBL14283979 | 0.70 | KDM4E (0.40) | — | |
| SCHEMBL14617069 | 0.70 | MEN1 (0.40) | PIM1ERN1 | |
| SCHEMBL21360123 | 0.69 | CYP3A4 (0.38) | ERN1 | |
| SCHEMBL12035880 | 0.69 | TRIM24 (0.40) | ERN1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| US-6506763-B2 | Useful in prevention and treatment of protein kinase related disorders such as cancer | SUGEN, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-0700388-B1 | SUBSTITUTED BETA-ARYL AND BETA-HETEROARYL-ALPHA-CYANOACRYLAMIDE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-09-18 | — | — | EP | disclosed |
| US-6133305-A | PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5652250-A | TYROSINE KINASE INHIBITORS | PHARMACIA S.P.A. (IT) | 1997-07-29 | — | — | US | disclosed |
| US-5639884-A | ANTITUMOR AGENTS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1997-06-17 | — | — | US | disclosed |
| US-5587385-A | TYROSINE KINASE INHIBITOR | FARMITALIA CARLO ERBA S.R.L. (IT) | 1996-12-24 | — | — | US | disclosed |
| EP-0700388-A1 | SUBSTITUTED BETA-ARYL AND BETA-HETEROARYL-ALPHA-CYANOACRYLAMIDE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1996-03-13 | — | — | EP | disclosed |
| WO-1995026341-A1 | SUBSTITUTED BETA-ARYL AND BETA-HETEROARYL-ALPHA-CYANOACRYLAMIDE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA S.P.A. (IT) | 1995-10-05 | — | — | WO | disclosed |
| EP-0549348-A1 | Arylidene-heterocyclic derivatives, process for their preparation and their use as tyrisine kinase inhibitors | PHARMACIA S.p.A. (IT) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PIM1 397/4885ERN1 1527/4885TRIM24 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.